The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- BIA 6-512 400 mg
- Conditions
- Parkinson Disease
- Sponsor
- Bial - Portela C S.A.
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Cmax - the maximum plasma concentration;
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of the study was to investigate the effect of food on the pharmacokinetics of a single 400 mg dose of BIA 6-512 (trans-resveratrol) in healthy volunteers
Detailed Description
Single-centre, open-label, randomised, two-way crossover study in 24 healthy male and female subjects. The study consisted of 2 single-dose periods separated by a washout of 7 days or more. Eligible subjects were admitted to the UFH on the day (Day 0) prior to receiving the dose of study medication (Day 1). On the morning of the next day (Day 1), a BIA 6-512 400 mg dose was administered following either a standard breakfast (Test) or at least 8 hours of fasting (Reference). Subjects remained confined in the UFH from admission (Day 0) until at least 24 h post dose (Day 2); then, they were discharged and returned for the second treatment period or a follow-up visit.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female subjects aged between 18 and 45 years, inclusive.
- •Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive.
- •Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, and 12-lead ECG.
- •Subjects who had clinical laboratory test results clinically acceptable at screening and admission to first treatment period.
- •Subjects who had negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening.
- •Subjects who had a negative screen for alcohol and drugs of abuse at screening and admission to each treatment period.
- •Subjects who were non-smokers or who smoke ≤ 10 cigarettes or equivalent per day.
- •Subjects who were able and willing to give written informed consent.
- •(If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier, intrauterine device or abstinence.
- •(If female) She had a negative urine pregnancy test at screening and admission to each treatment period.
Exclusion Criteria
- •Subjects who did not conform to the above inclusion criteria, OR
- •Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
- •Subjects who had a clinically relevant surgical history.
- •Subjects who had a clinically relevant family history.
- •Subjects who had a history of relevant drug or food hypersensitivity.
- •Subjects who had a history of alcoholism or drug abuse.
- •Subjects who consumed more than 21 units of alcohol a week.
- •Subjects who had a significant infection or known inflammatory process on screening or first admission.
- •Subjects who had acute gastrointestinal symptoms at the time of screening or first admission (e.g., nausea, vomiting, diarrhoea, heartburn).
- •Subjects who had used medicines within 2 weeks of first admission that, in the opinion of the investigator, may affect the safety or other study assessments.
Arms & Interventions
BIA 6-512 fed
BIA 6-512 400 mg following a standard meal
Intervention: BIA 6-512 400 mg
BIA 6-512 fasting
BIA 6-512 400 mg following at least 8 h of fasting
Intervention: BIA 6-512 400 mg
Outcomes
Primary Outcomes
Cmax - the maximum plasma concentration;
Time Frame: pre-dose and ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
Pharmacokinetic parameters of BIA 6-512 following a single-dose of 400 mg BIA 6-512 administered orally in fasting conditions and after a standard meal
tmax - the time of occurrence of Cmax
Time Frame: pre-dose and ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
Pharmacokinetic parameters of BIA 6-512 following a single-dose of 400 mg BIA 6-512 administered orally in fasting conditions and after a standard meal
AUC0-t - the area under the plasma concentration-time curve from time zero to the last sampling time at which concentrations are at or above the limit of quantification, calculated by the linear trapezoidal rule
Time Frame: pre-dose and ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
Pharmacokinetic parameters of BIA 6-512 following a single-dose of 400 mg BIA 6-512 administered orally in fasting conditions and after a standard meal